Skip to main content
PMC home page
eLife logoLink to eLife
. 2022 Jun 23;11:e79552. doi: 10.7554/eLife.79552

Filamentation modulates allosteric regulation of PRPS

Huan-Huan Hu 1,†, Guang-Ming Lu 1,†, Chia-Chun Chang 1,†, Yilan Li 1, Jiale Zhong 1, Chen-Jun Guo 1, Xian Zhou 1, Boqi Yin 1, Tianyi Zhang 1, Ji-Long Liu 1,2,✉
Editors: Edward H Egelman3, Volker Dötsch4
PMCID: PMC9232217  PMID: 35736577

Abstract

Phosphoribosyl pyrophosphate (PRPP) is a key intermediate in the biosynthesis of purine and pyrimidine nucleotides, histidine, tryptophan, and cofactors NAD and NADP. Abnormal regulation of PRPP synthase (PRPS) is associated with human disorders, including Arts syndrome, retinal dystrophy, and gouty arthritis. Recent studies have demonstrated that PRPS can form filamentous cytoophidia in eukaryotes. Here, we show that PRPS forms cytoophidia in prokaryotes both in vitro and in vivo. Moreover, we solve two distinct filament structures of E. coli PRPS at near-atomic resolution using Cryo-EM. The formation of the two types of filaments is controlled by the binding of different ligands. One filament type is resistant to allosteric inhibition. The structural comparison reveals conformational changes of a regulatory flexible loop, which may regulate the binding of the allosteric inhibitor and the substrate ATP. A noncanonical allosteric AMP/ADP binding site is identified to stabilize the conformation of the regulatory flexible loop. Our findings not only explore a new mechanism of PRPS regulation with structural basis, but also propose an additional layer of cell metabolism through PRPS filamentation.

Research organism: E. coli

Introduction

Phosphoribosyl pyrophosphate (PRPP) is an important intermediate in multiple metabolic pathways in cells. It is utilized in the biosynthesis of purine and pyrimidine nucleotides, histidine and tryptophan, and the cofactors NAD and NADP (Hove-Jensen, 1988; Munch-Petersen, 1983). PRPP is synthesized by PRPP synthase (PRPS), which catalyzes the transfer of diphosphate from ATP to ribose-5-phosphate (R5P), thereby generating AMP and PRPP (Khorana et al., 1958).

PRPS is essential for maintaining PRPP pool and cellular metabolic homeostasis. In humans, missense mutations of PRPP synthase isozyme 1 (PRPS1) alter enzyme activity or the allosteric regulation and are associated with many severe pathological outcomes (Becker et al., 1995; Chen et al., 2013; Duley et al., 2011). The decreased activity of this enzyme may result in neurological disorders, such as Arts syndrome, non-syndromic sensorineural deafness 2 (DFN2), Charcot-Marie-Tooth disease 5 (CMTX5), and retinal dystrophy. Conversely, hyperactivity of PRPS1 may lead to neurosensory defects, hyperuricemia, or gouty arthritis. Dysregulation of PRPS1 or PRPS2 activity and expression has been observed in many cancers and is associated with thiopurine resistance in recurrent childhood acute lymphoblastic leukemia (Cunningham et al., 2014; Li et al., 2015). Therefore, the precise regulation of PRPS is of great significance in metabolism and physiology.

In general, organisms contain at least one PRPS gene. According to the biochemical properties, PRPS of different species can be divided into three categories. Class I PRPP synthase is the most widely distributed in phylogeny, including E. coli and humans. Phosphate ion (Pi) is necessary to activate class I PRPS, while ADP, an allosteric inhibitor, competes with Pi and ATP at allosteric and active sites, respectively (Eriksen et al., 2000; Hove-Jensen et al., 1986; Nosal et al., 1993; Willemoës et al., 2000). However, class II PRPS is active without Pi. ADP does not bind to the allosteric site of the class II PRPS but inhibits it competitively (Krath et al., 1999; Krath and Hove-Jensen, 2001). Class III PRPS present in archaea requires Pi to activate, but there is no allosteric mechanism (Kadziola et al., 2005).

It is reported that in prokaryotes and eukaryotes, there is a kind of micron level metabolic enzyme filament, which is called cytoophidium (cytoophidia for plural) (Liu, 2016; Park and Horton, 2019; Zhou et al., 2020). The cytoophidium is assembled by bundling filamentous polymers of metabolic enzymes (Liu, 2016). Dozens of cytoophidium-forming enzymes are identified in the genome-wide screening of budding yeast (Noree et al., 2010; Shen et al., 2016). In mammalian cells, the presence of CTP synthase (CTPS) and IMP dehydrogenase (IMPDH) cytoophidium is proposed to be correlated with the metabolic characteristics of specific tissues such as cancer and immune cells (Calise et al., 2018; Chang et al., 2017; Duong-Ly et al., 2018). The polymerization of human CTPS1 and IMPDH2 have been demonstrated to desensitize proteins to end-product inhibition or allosteric inhibition, indicating their physiological functions in tuning intracellular nucleotide levels (Anthony et al., 2017; Lynch et al., 2017). In addition, we have found asparagine synthase and proline synthesis enzyme P5CS form cytoophidia (Zhang et al., 2020a; Zhang et al., 2018; Zhang et al., 2021; Zhong et al., 2022). Recently, PRPS has been identified as a novel cytoophidium-forming enzyme in various eukaryotes, including budding yeast, fruit flies, zebrafish, and mammals (Begovich et al., 2020; Noree et al., 2019). The evolutionary conservation of PRPS filamentation implies the physiological roles of this structure. Moreover, PRPS, as the upstream enzyme of CTPS and IMPDH, indicates that the regulation of enzyme function through filamentation is particularly important for de novo nucleotide biosynthesis. Although the high-resolution structures of human, Bacillus subtilis and E. coli PRPS hexamers have been solved from several crystal forms (Chen et al., 2015; Eriksen et al., 2000; Li et al., 2007; Zhou et al., 2019a), the filamentation of PRPS remains largely unknown. Therefore, we aim to reveal the structure, function, and potential mechanism of PRPS filament.

In the present study, we find that E. coli PRPS can form filaments in vitro and in vivo. Using cryo-electron microscopy (cryo-EM), we solve two types of PRPS filaments with near-atomic resolution of 2.3–2.9 Å. Structural and biochemical analyses indicate that the formation of type A filament attenuates the allosteric inhibition. In addition, the conformational changes of the regulatory flexible loop (RF loop) suggest that it plays a role in the regulation of allosteric inhibition and ATP binding. A noncanonical allosteric binding site for AMP and ADP binding is identified in the type A filament, which participates in the regulation of the RF loop. Altogether, our findings reveal a novel mechanism of structural regulation of E. coli PRPS, and provide new insights into PRPS-related human disorders and potential clinical and industrial applications.

Results

PRPS hexamers assemble into two types of filaments

There is only one PRPS gene in E. coli genome, which has 47.5% sequence identity to human PRPS1 and PRPS2 (Tatibana et al., 1995). Recently, PRPS cytoophidium has been observed in various organisms, suggesting PRPS can form filamentous polymers. To elucidate the functions and potential molecular mechanism of PRPS filamentation, the structures of PRPS polymers were analyzed.

We expressed and purified E. coli PRPS from E. coli K12 strain in Transetta (DE3) cells, and analyzed its structures under cryo-EM. In order to determine the conditions for inducing PRPS polymerization, we incubated PRPS protein with its known ligands and examine it under negative staining electron microscopy. We provide cryo-EM data and model refinement statistics in Table 1.

Table 1. Statistics of Cryo-EM structures in this study.

ecPRPS type A filament ecPRPS type B filament ecPRPS type AAMP/ADP filament
(EMD-33305, PDB 7XMU) (EMD-33309, PDB 7XN3) (EMD-33306, PDB 7XMV)
Data collection and processing
EM equipment Titan Krios Titan Krios Titan Krios
Detector K3 camera K3 camera K3 camera
Magnification 22,500 x 22,500 x 22,500 x
Voltage (kV) 300 300 300
Electron exposure ((e–/Å2)) 60 60 60
Defocus range(μm) –1.0 to –2.5 –1.0 to –2.5 –1.0 to –2.5
Pixel size(Å) 0.53 0.53 0.53
Symmetry imposed D3 D3 D3
Number of collected movies 3,474 3,131 2,566
Initial particle images (no.) 887,654 1186879 1066797
Final particle images (no.) 70,541 168,218 53,045
Map resolution (Å) 2.3 2.9 2.6
 FSC threshold 0.143 0.143 0.143
Map resolution range (Å) 2.3–3.4 2.8–4.7 2.5–4.6
Refinement
Initial model used (PDB code) 4S2U 4S2U 4S2U
Map sharpening B-factor(Å2) –45 –98 –51
Model composition
 Non-hydrogen atoms 15,294 14,016 15,228
 Protein residues 1,842 1,830 1,842
 Ligands ADP, HSX, PO4, MG PO4 AMP, HSX, ADP, MG
 Waters 822 54 810
 Ions 18 12 12
B factors(Å2)
Protein 49 65 57
 Ligand 55 67 58
 Water 50 57 57
R.m.s. deviations
 Bond lengths (Å) 0.005 0.005 0.008
 Bond angles (°) 0.736 0.609 0.800
Validation
 MolProbity score 1.48 2.11 1.58
 Clashscore 4.23 6.13 5.31
 Poor rotamers (%) 1.57 2.37 1.18
Ramachandran plot
 Favored (%) 97.36 92.08 96.37
 Allowed (%) 2.64 7.92 3.63
 Disallowed (%) 0 0 0
Open in a new tab

ADP and Pi are well-known regulators of PRPS. Although ADP inhibits PRPS through allosteric inhibition and competitive inhibition, Pi competes with ADP at the allosteric site, which is required for catalysis. In addition, Mg2+ is known to promote ATP binding at the active site (Gibson and Switzer, 1980).

When PRPS was incubated without ligands, no filaments were found, indicating that E. coli PRPS was not easy to polymerize. PRPS filaments were also not found with only AMP (2 mM). However, when PRPS was incubated only with ATP or any adenine nucleotide and Mg2+ (10 mM), many PRPS filaments could be observed. On the other hand, we also incubated PRPS at Pi concentrations of 10, 30, and 50 mM, and found that PRPS filamentated at 50 mM Pi (Figure 1—figure supplement 1).

We speculate that the conformation of PRPS polymer may change with the binding of different ligands. Therefore, we selected two conditions for structural analysis using cryo-electron microscopy (cryo-EM) and single-particle analysis. The first condition is the combination of ATP (2 mM) + Mg2+ (10 mM) and the second condition is only Pi (50 mM). These two conditions can induce PRPS filamentation without triggering the reaction, and the binding modes of most PRPS ligands are expected to be determined in the models. As a result, two distinct filament structures, type A (ATP and Mg2+) and type B (Pi) filaments were solved (Figure 1, Figure 1—figure supplements 2 and 3). In both models, PRPS hexamers are stacked in rows to form filamentous polymers. The twist and rise of type A filament are 27° (left-handed twist) and 63 Å, respectively, and the twist and rise of type B are 46° (left-handed twist) and 66 Å, respectively (Figure 1C and D).

Figure 1. with 8 supplements.

Overall structures of E. coli PRPS type A and type B filaments. (A) Type A filament ligands. The unit of E. coli PRPS type A filaments is hexamer with D3 symmetry. The hexamer has six identical ligand binding sites, one of which is shown in the figure. Different ligands are labeled with different colors. In type A filament, phosphate ion (Pi) binds to allosteric site 1, ADP binds to allosteric site 2 (red), and ATP binds to active site (brown). R5P also can be seen in the active site. (B) Type B filament ligands. The unit of type B filament is similar to that of type A filament, and one of the six identical ligand binding sites is shown here. In type B filament, the ATP binding site of active site is not bound by any ligand, while the R5P binding site and allosteric site 1 are bound by Pi. (C) Cryo-EM reconstruction of type A filament (C, 2.3 Å resolution). On the left is the electron density map of type A filament. On the right is the reconstruction structure of type A filament. The diameter and rise of type A filament are 110 Å and 63 Å, respectively. When hexamers are aggregated into type A filament, the adjacent hexamer us twisted by 27°. (D) Cryo-EM reconstructions of type B filament (2.9 Å resolution). On the left is electron density map of type A filament. On the right is the reconstruction structure of type A filament. The diameter of type B filament is same as that of type A filament. The rise and twist of type B filament are 66 Å and 46°, respectively.

Figure 1.

Figure 1—figure supplement 1. E. coli PRPS is assembled into filaments in vitro.

Figure 1—figure supplement 1.

Negative staining electron microscopic images of purified E. coli PRPS (1 μM) incubated in various conditions. The concentrations of nucleotides and Mg2+ are 2 mM and 10 mM, respectively.
Figure 1—figure supplement 2. Cryo-EM data processing of PRPS type A filament.

Figure 1—figure supplement 2.

(A) Representative Cryo-EM image of PRPS type A filament. (B) Representative 2D averages of PRPS type A filament in different views. (C) Local resolution of the type A filament final density map. (D) Gold-standard FSC curves of central hexamer in type A filament density map (dash line shows FSC = 0.143). The final average resolution of hexamer is estimated to be 2.3 Å. (E) Flow chart of PRPS type A filament image processing.
Figure 1—figure supplement 3. Cryo-EM data processing of PRPS type B filament.

Figure 1—figure supplement 3.

(A) Representative Cryo-EM image of PRPS type B filament. (B) Representative 2D averages of PRPS type B filament in different views. (C) Local resolution of the type B filament final density map. (D) FSC curves of central hexamer in type B filament density map (dash line shows FSC = 0.143). The final average resolution of hexamer is estimated to be 2.9 Å. (E) Flow chart of PRPS type B filament image processing.
Figure 1—figure supplement 4. Electron density maps of type A and type AAMP/ADP in allosteric site and active site.

Figure 1—figure supplement 4.

On the left are ligands of type A filament (chains are gray). On the right are ligands of type A AMP/ADP filament (chains are cyan). All ligands in the electron density map are listed separately. Red spheres indicate H2O and green spheres indicate Mg2+.
Figure 1—figure supplement 5. Structure analysis of PRPS type AAMP/ADP filament.

Figure 1—figure supplement 5.

(A) The model of E. coli PRPS parallel dimer in type AAMP/ADP polymer . (B) Cryo-EM reconstruction of type AAMP/ADP (2.6 Å resolution) PRPS polymers (left). Comparison of overall structures of type A (gray) and type AAMP/ADP (cyan) filaments. (C) Comparison of ligands for type A (blue) and type AAMP/ADP (magenta) filaments. (D) Electron density map of ADP (type A) and AMP (type AAMP/ADP) in allosteric site 2.
Figure 1—figure supplement 6. Cryo-EM data processing of PRPS type AAMP/ADP filament.

Figure 1—figure supplement 6.

(A) Representative Cryo-EM image of PRPS type B filament. (B) Representative 2D averages of PRPS type AAMP/ADP filament in different views. (C) Local resolution of the type B filament final density map. (D) FSC curves of central hexamer in type AAMP/ADP filament density map (dash line shows FSC = 0.143). The final average resolution of hexamer is estimated to be 2.6 Å. (E) Flow chart of PRPS type AAMP/ADP filament image processing.
Figure 1—figure supplement 7. Representative Cryo-EM density maps of individual regions of the PRPS type A filament.

Figure 1—figure supplement 7.

Figure 1—figure supplement 8. Representative Cryo-EM density maps of individual regions of the PRPS type B filament.

Figure 1—figure supplement 8.

Open in a new tab

Surprisingly, in type A filament, we found R5P at the active site, and the ATP binding site was occupied by ADP rather than ATP. In addition, another ADP is located at a noncanonical binding site (allosteric site 2), which is bound by AMP in the Legionella pneumophila PRPS structure (PDB ID: 6NFE), while Pi is located at the binding position of the β-phosphate of ADP at the canonical ADP allosteric site (allosteric site 1) (Figure 1A, Figure 1—figure supplement 4).

Since we did not add ADP to the mixture for sample preparation, ADP in the model might come from the spontaneous hydrolysis of ATP or be preserved during protein purification. The latter scenario can also explain the unexpected presence of R5P in the model. Meanwhile, in type B filament, R5P binding site and allosteric site 1 are bound by Pi, while ATP binding site and allosteric site 2 are empty (Figure 1B).

The structural comparison between the two models shows that the PRPS monomers in type A and type B filaments are highly similar except for the regulatory flexible loop region (RF loop, Y94 to T109) (Figure 2A). The main difference between the hexamers in the two filaments lies in the relative position of the monomers in the parallel dimer. The 5.2° rotation of hexamer leads to closed (type A) and open (type B) conformations (Figure 2B–D, Figure 2—video 1).

Figure 2. The structural comparison of E. coli PRPS type A and type B filaments.

(A) Monomers in the closed (pink for type A polymer) and open (yellow for type B polymer) hexamers. In the monomer of type A and type B polymers, the RF loop is green and red respectively. The shift of RF loop is about 9 Å. (B) Structural comparison of hexamers of the type A (pink and gray) and type B (yellow and blue). Structural comparison of parallel and bent dimers in of type A (C, pink and gray) and type B (D, yellow and blue) filament hexamers.

Figure 2.

Figure 2—video 1. Structural transition of ecPRPS hexamer conformations in type A and type B polymers.
Download video file (2.6MB, mp4)
Morph from the ecPRPS hexamer of type A filament to the type B filament. RF loop is green (type A) and red (type B), respectively.
Open in a new tab

Ligand binding modes in type A filaments

In the type A filament model, R5P and ADP at the active site are in association with two Mg2+. One Mg2+ (Mg site 1) coordinates the C1, C2, and C3 hydroxyl groups of R5P with D170 and two water molecules, and the other Mg2+ (Mg site 2) coordinates oxygens of the α- and β-phosphates of ADP (active site) with H131 and three water molecules (Figure 3A and B, Figure 1—figure supplement 4). The ADP at the active site of chain B forms hydrogen bonds with D37 in chain C, and there is a π-π interaction between F35 in chain C and adenine base. R99 and H131 in chain B form salt bridges with the β and α-phosphate, respectively (Figure 3B and C). The α-phosphate of the ADP also interacts with R5P through hydrogen bonds with the C-1 hydroxyl group. R5P of chain B forms hydrogen bonds with D170, D220, D221, T225, and T228 in the same chain (Figure 3B and C).

Figure 3. with 2 supplements.

Ligand binding modes in E. coli PRPS type A and type B filaments. (A) Hexamer of type A filament. Each chain is marked with a different color. (B) ADP and R5P are identified on the active site of PRPS in type A filament, while allosteric site 1 is bound by Pi and allosteric site 2 is bound by ADP. The residues that interact with ligands are indicated. Residues in chain A number with the # symbol and in chain C number with the * symbol. Residues in red are conserved in various organisms. Each chain is marked with a different color(dash lines in cyan indicate hydrogen bonds). (C) Ligands of the active site of type A filament. ADP and Mg2+ occupy ATP binding sites at active sites. R5P and Mg2+ can also be seen in the active site. Residues in red are conserved in various organisms. Each chain is marked with a different color. (D) ADP in allosteric site 2 of type A filament. Residues in red are conserved in various organisms. Each chain is marked with a different color. (E) Hexamer of type B filament. Each chain is marked with a different color. (F) In type B filament, the ATP binding site of the active site is not bound by any ligand, while the R5P binding site and allosteric site 1 are bound by Pi. Residues in chain A number with the # symbol and in chain C number with the * symbol. Residues in red are conserved in various organisms. Each chain is marked with a different color(dash lines in yellow indicate hydrogen bonds).

Figure 3.

Figure 3—figure supplement 1. Structure comparison of PRPS in various organisms.

Figure 3—figure supplement 1.

(A) Structural comparison of ecPRPS models in type A and type B polymers, Legionella pneumophila PRPS (6NFE), human PRPS1 (2H06), Bacillus subtilis PRPS (1DKU) bound with phosphomethylphosphonic acid adenosyl ester and methyl phosphonic acid adenosine ester, and Bacillus subtilis PRPS (1DKR) containing sulfate ion. (B and C) Structure comparison of ecPRPS models in type A polymers and human PRPS1(2HCR). Ligands of the active sites and allosteric sites were displayed in (B). In the structure of human PRPS1(2HCR), AMP occupy ATP binding sites, SO42+ and Cd2+ bind in the R5P binding region. SO42+ can also be seen in the allosteric site 1 and allosteric site 2. In the structure of ecPRPS hexamer in type A polymers, ADP and Mg2+ occupy ATP binding sites, R5P and Mg2+ bind in the R5P binding region. Pi bind in the allosteric site 1, and ADP can be seen in the allosteric site 2. (C) Structure comparison of the allosteric 2 in ecPRPS type A polymers and human PRPS1. The residues that interact with ligands are indicated. Residues in the human PRPS1 structure number with the ’ symbol.
Figure 3—figure supplement 2. Comparison of PRPS sequences of various organisms.

Figure 3—figure supplement 2.

Sequence alignment of Escherichia coli (strain K12), Salmonella typhimurium (strain LT2 /SGSC1412/ATCC 700720), Bacillus subtilis (strain 168), Mycobacterium tuberculosis (strain ATCC 25618/H37 Rv), Homo sapiens (Human), Mus musculus (Mouse) and Saccharomyces cerevisiae (strain ATCC 204508/S288 c) (Baker’s yeast). The conserved residues are indicated in red, and secondary structure elements are indicated above.
Open in a new tab

ADP binds allosteric site 2 in chain A through hydrogen bonding with R102 in chain B, and S149, E133 in chain A, and a π-π interaction between F147 of chain A and adenine bases, and salt bridges between R102 in chain B, R178 in chain A, and phosphates (Figure 3D, Figure 1—figure supplement 5). Allosteric site 2 binds to AMP in Legionella pneumophila PRPS structure (PDB ID: 6NFE), which is adjacent to allosteric site 2 bound with SO42+ in multiple human PRPS1 structures (PDB ID: 2H06 and 2HCR) (Figure 3—figure supplement 1). Parallel to the above two structures, we also solved another type A filament (type AAMP/ADP), which was formed under the conditions of AMP (2 mM)+ADP (2 mM) (Figure 1—figure supplement 5). This structure is almost the same as the former type A filament model, but its allosteric site 2 is bound by AMP rather than ADP (Figure 1—figure supplement 5). In addition, the allosteric site 1 in type AAMP/ADP model is empty, supporting that the presence of ADP and Pi in the former type A filament model were due to spontaneous hydrolysis of ATP. According to our two type A filament models, the allosteric site 2 of E. coli PRPS may accommodate both AMP and ADP. Allosteric site 2 bound with AMP/ADP in E. coli lies in space adjacent to allosteric site 2 bound with SO42+ in human PRPS1, suggesting that these two noncanonical allosteric sites are functionally related (Figure 3—figure supplement 2).

Dynamic RF loop reveal novel regulatory mechanisms of PRPS

In the model of type B filament, allosteric site 1 is bound by Pi and allosteric site 2 is incomplete due to the conformational change of hexamer from closed to open (Figure 3E and F). The 5-phosphate of R5P on the active site is replaced by Pi (Figure 3F). Intriguingly, our density map shows that the ATP binding site in the active site is not bound by the ligand, but occupied by the RF loop (Figure 4A).

Figure 4. Conformational changes of the RF loop.

Figure 4.

Open in a new tab

(A) Comparison of RF loop structures in type A (pink and gray) and type B (yellow and blue) filaments. In type B filament, the RF loop partially occupies the active site that blocks nucleotide binding. (B) Comparison of RF loop structures between type B filament and Bacillus substilis PRPS (PDB ID: 1DKU). Residues in 1DKU number with the ’ symbol. (C) B factors are shown on the RF loop of type A and type B filament models. (D) Structural comparison shows that the Bacillus substilis PRPS (PDB ID: 1DKU) model, the RF loop in type A filament overlaps with ADP at allosteric site 1. Residues in 1DKU number with the ’ symbol.

This conformation of the RF loop differs from previous structures including the Bacillus substilis PRPS (PDB ID: 1DKU) (Figure 4B, Figure 3—figure supplement 1). The B-factor of the RF loop in the type B filament ranges from 50.5 to 93.3 Å2, indicating its flexibility (Figure 4C). However, in type A filaments, the RF loop is stabilized by a variety of interactions, including the salt bridge between R102 and α-phosphate of ADP at allosteric site 2, resulting in smaller B factors ranges from 29.4 to 44.5 Å2 (Figure 4C).

On the other hand, the RF loop in type A filament is stabilized at a conformation and covers the ADP binding pocket at allosteric site 1. This conformation results in the closure of allosteric site 1, thereby preventing the binding of allosteric inhibitor ADP (Figure 4D). This may also explain the fact that ADP does not bind to allosteric site 1 in type AAMP/ADP filament, although its binding competitor Pi is absent (Figure 1—figure supplement 5).

Distinct contacts of PRPS hexamers in type A and B filaments

In the two filament models, the relative positions of PRPS monomers of parallel dimers are different, resulting in different contact interfaces between the two PRPS hexamers. In type A filaments, hexamers are connected by salt bridges formed between R301 and E298 pairs, by the hydrogen bonds between R301, N305, and E307, and also by van der Waals force between R302 and R301 (Figure 5A). In the type B filament, the connection between hexamers relies on the π-cation interaction between Y24 and R22, and the hydrogen bond between R301 and L23 (Figure 5B). These different interfaces may prevent the polymerization of heterogenous hexamers.

Figure 5. Distinct contacts of hexamers in E. coli PRPS type A and B filaments.

Figure 5.

Open in a new tab

(A and B) Maps and models of type A (A) and type B (B) filaments reveal distinct interfaces between adjacent hexamers in the two types of filaments. Residues responsible for the interactions are indicated. Residues in another hexamer number with the * symbol.

In order to investigate the functions of these two types of filaments, we have generated PRPSR302A and PRPSY24A respectively to disrupt the formation of type A and type B filaments. We also generated a mutant PRPS (PRPSR302A/Y24A) carrying both R302A and Y24A mutations, which may not be able to form filaments. The ability of each PRPS mutant to form type A and type B filaments was evaluated under negative staining electron microscopy. As expected, PRPSR302A/Y24A failed to assemble filaments under all conditions, and PRPSR302A and PRPSY24A could only form type B and type A filaments, respectively (Figure 6A).

Figure 6. Filamentation regulates allosteric inhibition of E. coli PRPS.

(A) Under the condition of inducing type A and type B filaments, the negative staining electron microscopic images of wild-type and mutant E. coli PRPS. Scale bars = 100 nm. (B) The graph shows the catalytic activity of wild-type and mutant E. coli PRPS with various amounts of ADP (Tukey’s test). (C) Bar graph shows the catalytic activity of wild-type and mutant E. coli PRPS in the reaction mixtures containing different amounts of ATP and ADP (Student’s t-test). Error bars = standard error of the mean (S.E.M.). *p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001.

Figure 6.

Figure 6—figure supplement 1. Catalytic activity of E. coli PRPS with different concentrations of ligands.

Figure 6—figure supplement 1.

Graphs show the catalytic activity of wild-type E. coli PRPS in the presence of different amounts of ATP (A), R5P (B), phosphate ion (C), and AMP (D). Error bars = standard error of the mean (S.E.M.). All tests are repeated three times.
Open in a new tab

Filamentation regulates allosteric inhibition of PRPS

To elucidate the function of PRPS filamentation, the in vitro activity of PRPS was determined by coupling reaction. In the reaction mixture, the newly synthesized PRPP by PRPS would be subsequently utilized by phosphoribosyltransferase (OPRT) in the reaction orotate (OA) +PRPP → orotidine 5'-monophosphate (OMP) +PPi (Krungkrai et al., 2005). Therefore, the PRPP production could be measured by the consumption of OA, and the absorbance of OA is 295 nm.

In the absence of ADP, we found the substrate concentration used in the assay (0.6 mM ATP, 0.6 mM R5P), PRPS catalyzed the reaction at the maximum rate (Figure 6—figure supplement 1A,B). Pi is known as an activator of class I PRPS. PRPS production could not be detected without Pi (Figure 6—figure supplement 1C). When different concentrations of Pi were added to the reaction mixtures, the activity peaked at 5–10 mM and gradually decreased at higher concentrations (Figure 6—figure supplement 1C). Therefore, we used 0.6 mM ATP, 0.6 mM R5P, and 10 mM Pi and different concentrations of ADP to analyze the activity of each PRPS mutants.

In the absence of ADP, the activity of PRPSR302A decreased significantly, while the activity of PRPSR302A/Y24R was higher (Figure 6B). When ADP (0.1 mM) was added into the mixture, the activity of PRPSR302A and PRPSR302A/Y24A dropped dramatically by 82.3% and 85.1% respectively, whereas the activities of PRPSWT and PRPSY24A decreased only by 37.8% and 18.9%, respectively (Figure 6B). With the increase of ADP concentration, the activity of each group decreased gradually. However, PRPSR302A and PRPSR302A/Y24R were nearly inactive when ADP concentration was higher than 0.2 mM.

ADP inhibits PRPS through allosteric and competitive inhibition. The inhibition we observed in these conditions may be a combination of these two mechanisms. To reduce competitive inhibition, we then increased the ATP concentration to 2 mM (Figure 6C). When ADP was not present, the increase of ATP concentration did not change the activity of all PRPS. However, when ADP (0.1 mM) was supplied, activity deceased in most groups (Figure 6C). The activity of PRPSWT and PRPSR302A dropped by 32.2% and 91.6%, respectively. The only exception is PRPSY24A, whose activity has not changed, indicating that the absence of type B filament leads to significant resistance to allosteric inhibition. After adding ADP, the activity of PRPSR302A/Y24R decreased by 55.4%, indicating that filamentation is not required for allosteric inhibition. Although it is unlikely that all PRPS were within filaments during the measurement, these results still show that polymerization significantly affects the activity of PRPS under these in vitro conditions. Our findings on conformational changes of RF loop may explain the resistance of type A filaments to allosteric inhibition of ADP.

AMP/ADP at the allosteric site 2 facilitate ATP binding

The inhibitory function of the allosteric site 1 is well-known, although the molecular mechanism is still uncertain (Hove-Jensen et al., 2017). The function of the allosteric site 2, however, is largely unclear. According to our model, allosteric site 2 can be bound by AMP and ADP. It is worth noting that AMP is also one of the products in the reaction. The type AAMP/ADP filament model suggests that allosteric site 2 may favor AMP over ADP. That is, allosteric site 2 may bind to AMP under all reacting conditions. Nevertheless, we measured PRPS activity at different AMP levels and found no significant difference among groups (Figure 6—figure supplement 1D).

Our model suggests that AMP/ADP at allosteric site 2 may contribute in the stabilization of the RF loop through the interaction between R102 and α-phosphate of ADP or AMP. Since the stabilization of the RF loop is expected to prevent ADP from entering allosteric site 1 and avoid the interference RF loop on ATP binding, we suspect that AMP/ADP at allosteric site 2 may enhance PRPS activity. Therefore, we intended to impair the interaction between the C2 hydroxyl group of ADP and the side chain of E133 by introducing the point mutation E133A. As expected, when ATP was 0.6 mM, the activity of PRPSE133A was four times lower than that of PRPSWT. However, when ATP was increased to 2 mM, the activity of PRPSE133A increased to a level comparable to that of PRPSWT. Corresponding human PRPS1S132A mutant also displayed reduced activity in a previous study (Li et al., 2007). These results suggest that AMP/ADP at allosteric site 2 may facilitate the binding of ATP at the active site (Figure 6C).

E. coli PRPS filaments assemble into cytoophidia in vivo

Filamentous polymers of various metabolic enzymes have been shown to bundle into a large filamentous structure, the cytoophidium, in a broad spectrum of organisms. PRPS cytoophidia have been observed in multiple eukaryotes including mammals. We fused the sequences of PRPSWT and PRPSR302A, PRPSY24A and PRPSR302A/Y24A mutants with mCherry and overexpressed them in E. coli, respectively. In a small subset of cells (less than 1%), filamentous structures of PRPSWT-mCherry could be observed (Figure 7A). In contrast, PRPSR302A-mCherry filaments and punctate aggregates were observed in about 1% cells. In cells expressing PRPSY24A-mCherry, filaments were not found, but punctate aggregates were observed less than 1% cells. At all stages of growth, no filaments or punctate aggregates were observed in cells expressing PRPSR302A/Y24A-mCherry.

Figure 7. E. coli PRPS forms type A and type B filaments in vivo.

Figure 7.

Open in a new tab

(A) Representative images of Transetta E. coli strains overexpressing wild-type PRPS-mCherry and mutant PRPS-mCherry fusion proteins. Filamentous cytoophidia and punctate aggregates are indicated by arrowheads and arrows, respectively. Scale bars = 2 μm. (B) Growth curves of wild-type Transetta cells and cells overexpressing wild-type PRPS-mCherry and mutant PRPS-mCherry fusion proteins (Tukey’s test). Error bars = S.E.M. *p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001.

It is worth noting that the size of PRPS polymer may be within tens of nanometers, and the filaments or dots we observed with fluorescence microscope may be in a much larger scale. All forms of aggregates, filaments, and dots contain PRPS polymers, and dispersed polymers may also be present in cells without detectable aggregates.

Next, we analyzed the growth curve of E. coli overexpressing PRPS-mCherry proteins. The growth rate of cells overexpressing PRPSWT, PRPSR302A, and PRPSY24A was significantly faster than that of wild-type Transetta cells, while the growth rate of cells overexpressing PRPSR302A/Y24A was similar to that of wild-type cells (Figure 7B). Although we cannot rule out the unexpected effects of PRPS overexpression and mCherry tagging, our results show that both type A and type B PRPS filaments exist in vivo.

Discussion

The assembly of filamentous polymers has emerged as a common and conserved regulatory mechanism for many metabolic enzymes in eukaryotes, prokaryotes, and even archaea (Liu, 2016; Park and Horton, 2019; Zhou et al., 2020). Here, we show two types of filament structures of E. coli PRPS. Between E. coli and human PRPS1/2, the hexameric propeller structure of PRPS and the identified residues responsible for polymerization are conserved, indicating that type A and / or type B PRPS filaments may also exist in mammals. In fact, PRPS isolated from rat liver tissues revealed a heterogenous protein complex with a molecular weight greater than 1000 kDa (Kita et al., 1989). A similar phenomenon was observed in human PRPS1/2 isolated from tissue sources (Becker et al., 1977; Fox and Kelley, 1971). Furthermore, the recombinant human PRPS1/2 purified from E. coli can also be spontaneously assembled into large complexes larger than 1000 kDa in vitro (Nosal et al., 1993). Although these complexes are not necessarily filaments depicted in this study, collective evidence suggests that class I PRPS is regulated by the assembly of large complexes in bacteria and mammals.

Filamentous polymers of some metabolic enzymes have been demonstrated to accommodate different states of proteins. In most cases, their protomers in various states are assembled through the same interface, which can enhance (e.g. human IMPDH, CTPS and Drosophila CTPS) or inhibit (e.g. E. coli CTPS) activity (Johnson and Kollman, 2020; Lynch and Kollman, 2020; Zhou et al., 2021; Zhou et al., 2019b). In other cases, enzymes can polymerize into multiple polymer types (e.g. human acetyl-CoA carboxylase) through different interfaces (Hunkeler et al., 2018). Here, we reveal two distinct PRPS filament types that show different regulatory functions (Figure 8). The protomer of type A filament is PRPS hexamer in closed conformation, while type B filament is assembled from hexamer in open conformation. Different contact interfaces are used to connect PRPS hexamers in each filament type (Figures 5 and 6A), this means that the hexamer conformation may be homogenous in the individual filament and also implies that the proportion of closed/open hexamers may determine the formation of either type of filaments over the other. PRPS hexamer conformation could be regulated by the binding of ligands. For instance, the binding of Pi at the allosteric site 1 and AMP/ADP at site 2 may promote the closed hexamer conformation, while the ADP at site 1 would prevent the open-to-closed transformation. In addition, it is reasonable to suspect that polymerization may also contribute to the conformation stability of hexamers. In a relatively simple environment, only one type of filament may be produced (Figure 8). We used a very high amount of Pi (50 mM) to induce type B filament. The substitution of R5P by Pi at the active site may not represent the physiological situation. However, our activity assay and live cell imaging suggest these two types of filaments coexist in more complex mixtures or cells. This mechanism provides a new PRPS regulatory layer that can fine tune the production of PRPP and coordinate cellular metabolic pathways.

Figure 8. Schematic model of regulation and function of E. coli PRPS filaments.

Figure 8.

Open in a new tab

E. coli PRPS can form type A filament and type B filament to precisely regulate enzyme activity. ADP and phosphate (Pi) are allosteric regulators of PRPS. They can bind at allosteric sites or active sites. When incubated with ATP, ADP or AMP and R5P and Mg2+, PRPS can form type A filament to disrupt allosteric inhibition. When incubated with Pi, PRPS can form type B filament to increase allosteric inhibition.

ADP is an effective PRPS inhibitor because it can reduce the activity of rat PRPS by about 40~50% at a concentration of 0.1 mM (Tatibana et al., 1995). Consistent with previous studies (Willemoës et al., 2000), we showed that when 0.1 mM ADP was added into the reaction mixture, the PRPSWT activity of E. coli decreased by about 40% (Figure 6B and C). It is not clear how ADP at allosteric site 1 reduces the activity, although a molecular model has been proposed by comparing the three-dimensional structures of various B. subtilis PRPP synthase complexes (Hove-Jensen et al., 2017). Unfortunately, our structural analysis could not provide additional information to this mechanism. However, we show that this allosteric inhibition by ADP could be compromised by the formation of type A filaments (Figure 6B). In addition, our data illustrate a clear model for the resistance mechanism. In this model, the RF loop moves toward allosteric site 1, thereby enclosing the ADP binding pocket. A similar mechanism has been depicted in a previous report on human PRPS1 crystal structures, in which the adjacent allosteric site 2 is bound by SO42- (Li et al., 2007). These suggest that PRPS filamentation is not essential for the regulatory function of allosteric site 2, but could enhance such an effect. Since intracellular ADP level is generally within the range of hundreds micromolar in E. coli and mammalian cells (Meyrat and von Ballmoos, 2019; Traut, 1994), it is reasonable to propose that type A filament facilitates PRPP production in cells (Traut, 1994). On the other hand, we find the RF loop in the type B filament is unstable. The new conformation of the RF loop in our model indicates that the conformational changes of this loop may also participate in the regulation of ATP binding and catalytic activity (Figure 4B and C). Collectively, our data demonstrate the important role of the RF loop in regulating PRPS activity in two ways.

In addition, our model also explains the regulation of conformational change of RF loop. In our type A filament model, additional allosteric site 2 binds to AMP/ADP (Figure 3D and Figure 3—figure supplement 1). AMP/ADP at this binding site interacts with the RF loop, thereby stabilizing the loop at allosteric site 1. In contrast, allosteric site 2 is incomplete in the PRPS open hexamer (type B filament) and cannot bind to AMP/ADP, resulting in an unstable RF loop (Figure 4A and C). The point mutation E133A is expected to impair allosteric site 2, resulting in a significant decrease in activity, which supports our hypothesis about the function of allosteric site 2.

PRPS mutants have been used to improve the production of commercial compounds with PRPP as intermediate. For instance, feedback-resistant mutant PRPS has been shown to increase the synthesis of riboflavin and purine nucleosides of R. gossypii and B. amyloliquefaciens, respectively (Jiménez et al., 2008; Zakataeva et al., 2012). Our findings reveal a new mechanism involved in the regulation of E. coli PRPS with structural basis. Considering the high conservation among class I PRPS, certain point mutations may be applicable to industry.

In humans, PRPS1 mutations lead to low or high activity of PRPP synthesis, which is related to various disorders. Some of these human PRPS1 mutants have been characterized at the molecular level (Becker et al., 1995). Inhibition kinetics indicated that they were not sensitive to the allosteric inhibition. Interestingly, mutations that lead to allosteric inhibition desensitization, such as D51H, L128I, D182H, A189V, and H192D, are almost exclusively located at the interface between the dimers in the hexamer (Becker et al., 1995). Whether these mutants are related to the abnormal conformations of open and closed hexamers require further investigation.

Cytoophidia are considered large filamentous polymer bundles of metabolic enzymes (Liu, 2016; Park and Horton, 2019). It has been suggested that many types of cytoophidia are correlated with specific cellular status in certain tissues. For instance, CTPS cytoophidia are widely distributed in Drosophila tissues, especially in proliferative cell types (Aughey et al., 2014; Liu, 2010; Zhang et al., 2020b). In mammals, CTPS cytoophidia have been found in mouse thymus and many human cancers (Chang et al., 2017; Peng et al., 2021). In addition to regulating enzyme activity, the cytoophidium may also protect component proteins from degradation (Lin et al., 2018; Sun and Liu, 2019a). Many factors, such as mTOR pathway, temperature, pH, osmolality, and protein post-translational modifications, have been shown to influence the assembly of cytoophidia in various organisms (Andreadis et al., 2019; Lin et al., 2018; Lynch and Kollman, 2020; Petrovska et al., 2014; Sun and Liu, 2019b; Wang et al., 2015; Zhang and Liu, 2019). Recently, PRPS cytoophidia have been reported in yeast, Drosophila, zebrafish, and mammalian cell lines (Begovich et al., 2020; Noree et al., 2019). We demonstrate that PRPS cytoophidium is also present in E. coli, which may have physiological significance.

In conclusion, we show that E. coli PRPS can assemble two types of filaments. Structural comparison and biochemical analysis reveal a novel mechanism to regulate PRPS activity through conformational changes of RF loop, which is modulated by noncanonical allosteric site 2. These results expand our understanding of the regulation of key steps in nucleotide biosynthesis and shed light on potential clinical and industrial applications.

Materials and methods

Key resources table.

Reagent type (species) or resource Designation Source or reference Identifiers Additional information
Gene (Drosophila melanogaster) PRPS Genbank P0A717
Strain, strain background (Escherichia coli) Transetta (DE3) TransGen Biotech
Recombinant DNA reagent pRSFDuet-6His In house
Commercial assay or kit BCA Protein Concentration Determination Kit (Enhanced) Beyotime P0010
Chemical compound, drug Benzamidine hydrochloride Sigma-Aldrich 434760–5 G
Chemical compound, drug Pepstatin A Sigma-Aldrich P5318-25MG
Chemical compound, drug Leupeptin hydrochloride microbial Sigma/Aldrich L9783-100MG
Chemical compound, drug PMSF MDBio P006-5g
Chemical compound, drug Ni-NTA Agarose QIAGEN 30,250
Chemical compound, drug Orotic acid Adamas 01102798 (74736A)
Chemical compound, drug ATP Takara 4,041
Chemical compound, drug D-Ribose 5 phosphate disodium salt BIOSYNTH CARBOSYNTH R-5600
Chemical compound, drug 5-phospho-D-ribose 1-diphosphate penta-sodium salt Sigma P8296-25 mg
Chemical compound, drug Adenosine 5'-monophosphate solarbio A9860-1
Chemical compound, drug Adenosine 5'-diphosphate sodium salt Sigma A2754-100MG
Other Nitinol mesh Zhenjiang Lehua Electronic Technology M024-Au300-R12/13 Cryo-EM grid preparation
Other Holey Carbon Film Quantifoil R1.2/1.3, 300 Mesh, Cu Cryo-EM grid preparation
Other 400 mesh reinforced carbon support film EMCN BZ31024a Negative staining
Software, algorithm UCSF Chimera https://doi.org/10.1002/jcc.20084 https://www.cgl.ucsf.edu/chimera
Software, algorithm UCSF Chimera X https://doi.org/10.1002/pro.3235 https://www.cgl.ucsf.edu/chimerax/
Software, algorithm Relion https://doi.org/10.7554/eLife.42166 https://relion.readthedocs.io/en/latest/index.html#
Software, algorithm Coot https://doi.org/10.1107/S0907444910007493 https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/
Software, algorithm Phenix https://doi.org/10.1107/S2059798318006551 https://phenix-online.org/
Open in a new tab

Expression and purification of E. coli PRPS

Full-length of wild-type or mutant E. coli PRPS sequences with a C-terminal 6×His tag were cloned into a modified pRSFDuet vector at the MCS 2 site and expressed in E. coli Transetta (DE3) cells. After induction with 0.1 mM IPTG at the OD600 range of 0.5~0.8, the cells were cultured at 37 °C for 4 hr and pelleted by centrifugation at 4000 r.p.m. for 20 min. All remaining purification procedures were performed at 4 °C. The harvested cells were resuspended in cold lysis buffer (50 mM Tris HCl pH8.0, 500 mM NaCl, 10% glycerol, 10 mM imidazole, 5 mM β-mercaptoethanol, 1 mM PMSF, 5 mM benzamidine, 2 μg/ml leupeptin and 2 μg/ml pepstatin). After ultrasonication, the cell lysate was then centrifuged (18,000 r.p.m.) at 4 °C for 45 min. The supernatant was collected and incubated with equilibrated Ni-NTA agarose beads (Qiagen) for 1 hr. Subsequently, the column was further washed with lysis buffer supplemented with 50 mM imidazole. Target proteins were eluted with elution buffer containing 50 mM Tris HCl pH8.0, 500 mM NaCl, 250 mM imidazole, and 5 mM β-mercaptoethanol. Further purification was performed in column buffer (25 mM Tris HCl pH 8.0 and 150 mM NaCl) using HiLoad Superdex 200 gel-filtration chromatography (GE Healthcare). The peak fractions were collected, concentrated, and stored in small aliquots at −80 °C.

Cryo-EM grid preparation and data collection

To generate type A filaments, 6 μM PRPS protein was dissolved in a buffer containing 25 mM Tris HCl pH 7.5, 2 mM ATP, 10 mM MgCl2. ATP was replaced with 2 mM ADP and 2 mM AMP for generating type AAMP/ADP filaments. For type B filaments formation, 6 μM PRPS protein was incubated in a buffer containing 50 mM Na2HPO4 and 100 mM NaCl. All samples were incubated at 37 °C for 30 minutes and then loaded onto the grid. In order to prepare low-temperature cryo-EM grids, protein samples were loaded on a 300-mesh amorphous alloy grids (CryoMatrix M024-Au300-R12/13) with fresh glow discharge. Grids were blotted for 3.5 s with blot force of –1 at 4  °C and 100% humidity before plunge-freezing in liquid ethane with an FEI Vitrobot Mark IV (ThermoFisher Scientific).

Micrographs were collected in super-resolution counting mode with K3 Summit direct electron camera (Gatan) on FEI Titan Krios electron microscope at 300 kV. Automated data acquisition was performed with SerialEM (Mastronarde, 2005) at a nominal magnification of 22,500×, corresponding to a calibrated pixel size of 1.06 Å with a defocus range from 1.0 to 2.5 μm. Each movie stack was acquired in a total dose of 60 e−Å−2, subdivided into 50 frames at 4 s exposure.

image processing

All image processing steps were performed using Relion3.1-beta (Zivanov et al., 2018). Beam-induced motion correction and exposure weighting were performed by the MotionCorr2 (Zheng et al., 2017) and the CTF (contrast transfer function) parameter was estimated by CTFFIND4. For the type A filament dataset, 3045 images were manually selected and 887,654 particles were automatically picked up. Among them, after two rounds of fast 2D classification (extracting particles in binning 2) and another round of 2D classification (extracting particles in binning 1), 1438771 particles were selected for 3D classification. The featureless cylinder was reconstructed using the relion_helix_toolbox command and applied as a reference model for 3D classification. After two rounds of 3D classification using C1 and D3 symmetry, a total of 70,541 particles of the best category were selected for 3D auto-refinement, and each particle was subjected to CTF refinement and Bayesian polishing. Finally, the initial 2.8  Å density map including three layers of PRPS hexamer was ontained. A final 2.3  Å map was sharpened by post-process using a tight mask for the central hexamer with a B-factor of 45 Å2.

A similar procedure was performed for the type B filament dataset. A total of 1,186,879 particles were auto-picked from 2776 images. After multiple rounds of 2D classification and 3D classification, 168,218 particles were selected for 3D auto-refinement, and each particle was subjected to CTF refinement and Bayesian polishing. By using a compact mask with a B-factor of 98 Å for the central hexamer2, the optimal density map was sharpened to a nominal resolution of 2.9 Å.

For the type AAMP/ADP filament dataset, 1066797 particles were auto-picked from 1824 images. After multiple rounds of 2D classification and 3D classification, 53,045 particles were selected for 3D auto-refinement, and each particle is subjected to CTF refinement and Bayesian polishing. By using a compact mask with a B-factor of 51 Å for the central hexamer2, the optimal density map was sharpened to a nominal resolution of 2.6 Å. LocalRes was used to estimate the local resolution for all maps.

Model building and refinement

The Crystal structure of E. coli PRPS [Protein Data Bank (PDB) ID: 4S2U] was applied for the initial models of all datasets. The hexamer models were separated and docked into the corresponding electron density map using Chimera v.1.14 (Pettersen et al., 2004), followed by iterative manual adjustment and rebuilding in Coot (Emsley and Cowtan, 2004) and real-space refinement in PHENIX (Adams et al., 2011). The final atomic model was evaluated using MolProbity (Williams et al., 2018). The map reconstruction and model refinement statistics are listed in Table 1. All figures and videos were generated using UCSF Chimera and ChimeraX (Goddard et al., 2018).

PRPS activity assay

On a 96-well plate, the activity of PRPS was measured by coupled continuous spectrophotometry using SpectraMax i3. The PRPS reaction (ATP +R5 P → PRPP +AMP) is coupled the forward reaction (OA +PRPP → OMP +PPi) of E. coli orotate phosphoribosyltransferase (OPRT, EC 2.4.2.10) and the amount of PRPP generated in the reaction was determined by the reduction of in orotate (OA) in the mixture. The concentration of OA was measured by absorbance at 295 nm for 300 s at 25 °C (Krungkrai et al., 2005). Reaction mixture (200 μl) contains 0.1 μM PRPS, 1 mM OPRT, 1 mM OA, 10 mM MgCl2, 250 mM NaCl, 10 mM Na2HPO4, 0.6 mM R5P and AMP, ADP, ATP at concentrations as described in each experiment. ATP or R5P was least added into the mixture to initiate the reaction. All measurements were performed in triplicate.

Negative staining electron microscopy

The purified E. coli PRPS protein (1 μM) was dissolved in Tris-HCl buffer (25 mM Tris-HCl, 150 mM NaCl, 10 mM MgCl2, and 2 mM ATP or ADP) or Pi buffer (50 mM Na2HPO4, 300 mM NaCl). After incubation at 37 °C for 1 hr, the protein samples were loaded onto hydrophilic carbon-coated grids and washed twice with uranium formate. Subsequently, the grids were stained with uranium formate. Imaging was acquired with 120 kV electron microscope (Talos L120C, ThermoFisher, USA) with Eagle 4 K × 4 K CCD camera system (Ceta CMOS, ThermoFisher, USA) at ×57,000 magnification.

Sample preparation and confocal microscopy

E. coli cells were fixed with 4% formaldehyde at 37 °C, 220 r.p.m. for 10 min. After fixation, cells were collected by centrifugation at 12,000 r.p.m. for 1 min. Cell pellets were washed twice with PBS and then resuspended in PBS containing Hoechst33342. The cells were then incubated at room temperature for 1 hr. Add 2.5 μL of cell solution and 1 μL of pre-melted 1.2% low melting-point agar was mixed on the glass slide and covered with a coverslip for observation. Images were captured under Plan-Apochromat 63×/1.40 Oil DIC M27 objective on a Carl Zeiss LSM 800 (Axio Observer Z1) inverted fluorescence confocal microscope.

Growth curve

E. coli cells were pre-cultured overnight in 2 mL LB medium at 37 °C, 220 r.p.m., and then inoculated in 5 mL LB culture at 37 °C, 220 r.p.m. with OD600=0.05. The cell growth was determined by the OD600 value, which was measured by Eppendorf BioPhotometer D30 every hour after inoculation.

Acknowledgements

EM data were collected at the ShanghaiTech Cryo-EM Imaging Facility. We thank the Molecular and Cell Biology Core Facility (MCBCF) at the School of Life Science and Technology, ShanghaiTech University for providing technical support. This work was supported by grants from Ministry of Science and Technology of China (No. 2021YFA0804701-4), National Natural Science Foundation of China (No. 31771490), Shanghai Science and Technology Commission (No. 20JC1410500) and the UK Medical Research Council (grant nos. MC_UU_12021/3 and MC_U137788471) for grants to J.L.L.

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

Ji-Long Liu, Email: liujl3@shanghaitech.edu.cn, jilong.liu@dpag.ox.ac.uk.

Edward H Egelman, University of Virginia, United States.

Volker Dötsch, Goethe University, Germany.

Funding Information

This paper was supported by the following grants:

  • Ministry of Science and Technology of the People's Republic of China 2021YFA0804701-4 to Ji-Long Liu.

  • National Natural Science Foundation of China 31771490 to Ji-Long Liu.

  • Shanghai Science and Technology Commission 20JC1410500 to Ji-Long Liu.

  • Medical Research Council MC_UU_12021/3 to Ji-Long Liu.

  • Medical Research Council MC_U137788471 to Ji-Long Liu.

Additional information

Competing interests

No competing interests declared.

No competing interests declared.

Author contributions

Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review and editing.

Conceptualization, Formal analysis, Investigation, Validation, Writing – original draft.

Conceptualization, Investigation, Writing – original draft, Writing – review and editing.

Investigation.

Investigation.

Investigation.

Investigation.

Investigation.

Investigation.

Conceptualization, Funding acquisition, Project administration, Supervision, Writing – original draft, Writing – review and editing.

Additional files

MDAR checklist

Data availability

Atomic models generated in this study have been deposited at the PDB under the accession codes 7XMU, 7XMV, 7XN3. Cryo-EM maps deposited to EMDB as: EMD-33305, EMD-33306, EMD-33309.

The following datasets were generated:

Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A filament bound with ADP, Pi and R5P. RCSB Protein Data Bank. 7XMU

Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type B filament bound with Pi. RCSB Protein Data Bank. 7XN3

Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A(AMP/ADP) filament bound with ADP, AMP and R5P. RCSB Protein Data Bank. 7XMV

Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A filament bound with ADP, Pi and R5P. Electron Microscopy Data Bank. EMD-33305

Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A (AMP/ADP) filament bound with ADP, AMP and R5P. Electron Microscopy Data Bank. EMD-33306

Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type B filament bound with Pi. Electron Microscopy Data Bank. EMD-33309

References

  1. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Echols N, Headd JJ, Hung LW, Jain S, Kapral GJ, Grosse Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner RD, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. The Phenix software for automated determination of macromolecular structures. Methods (San Diego, Calif.) 2011;55:94–106. doi: 10.1016/j.ymeth.2011.07.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andreadis C, Hulme L, Wensley K, Liu JL. The TOR pathway modulates cytoophidium formation in Schizosaccharomyces pombe. The Journal of Biological Chemistry. 2019;294:14686–14703. doi: 10.1074/jbc.RA119.009913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anthony SA, Burrell AL, Johnson MC, Duong-Ly KC, Kuo YM, Simonet JC, Michener P, Andrews A, Kollman JM, Peterson JR. Reconstituted IMPDH polymers accommodate both catalytically active and inactive conformations. Molecular Biology of the Cell. 2017;28:2600–2608. doi: 10.1091/mbc.E17-04-0263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Aughey GN, Grice SJ, Shen Q-J, Xu Y, Chang C-C, Azzam G, Wang P-Y, Freeman-Mills L, Pai L-M, Sung L-Y, Yan J, Liu J-L. Nucleotide synthesis is regulated by cytoophidium formation during neurodevelopment and adaptive metabolism. Biology Open. 2014;3:1045–1056. doi: 10.1242/bio.201410165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Becker MA, Meyer LJ, Huisman WH, Lazar C, Adams WB. Human erythrocyte phosphoribosylpyrophosphate synthetase. Subunit analysis and states of subunit association. The Journal of Biological Chemistry. 1977;252:3911–3918. [PubMed] [Google Scholar]
  6. Becker MA, Smith PR, Taylor W, Mustafi R, Switzer RL. The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity. The Journal of Clinical Investigation. 1995;96:2133–2141. doi: 10.1172/JCI118267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Begovich K, Yelon D, Wilhelm JE. PRPS polymerization influences lens fiber organization in zebrafish. Developmental Dynamics. 2020;249:1018–1031. doi: 10.1002/dvdy.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Calise SJ, Abboud G, Kasahara H, Morel L, Chan EKL. Immune Response-Dependent Assembly of IMP Dehydrogenase Filaments. Frontiers in Immunology. 2018;9:2789. doi: 10.3389/fimmu.2018.02789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chang CC, Jeng YM, Peng M, Keppeke GD, Sung LY, Liu JL. CTP synthase forms the cytoophidium in human hepatocellular carcinoma. Experimental Cell Research. 2017;361:292–299. doi: 10.1016/j.yexcr.2017.10.030. [DOI] [PubMed] [Google Scholar]
  10. Chen P, Li J, Ma J, Teng M, Li X. A small disturbance, but A serious disease: the possible mechanism of D52H-mutant of human PRS1 that causes gout. IUBMB Life. 2013;65:518–525. doi: 10.1002/iub.1154. [DOI] [PubMed] [Google Scholar]
  11. Chen P, Liu Z, Wang X, Peng J, Sun Q, Li J, Wang M, Niu L, Zhang Z, Cai G, Teng M, Li X. Crystal and EM structures of human phosphoribosyl pyrophosphate synthase I (PRS1) provide novel insights into the disease-associated mutations. PLOS ONE. 2015;10:e0120304. doi: 10.1371/journal.pone.0120304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cunningham JT, Moreno MV, Lodi A, Ronen SM, Ruggero D. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell. 2014;157:1088–1103. doi: 10.1016/j.cell.2014.03.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Duley JA, Christodoulou J, de Brouwer APM. The PRPP synthetase spectrum: what does it demonstrate about nucleotide syndromes? Nucleosides, Nucleotides & Nucleic Acids. 2011;30:1129–1139. doi: 10.1080/15257770.2011.591747. [DOI] [PubMed] [Google Scholar]
  14. Duong-Ly KC, Kuo YM, Johnson MC, Cote JM, Kollman JM, Soboloff J, Rall GF, Andrews AJ, Peterson JR. T cell activation triggers reversible inosine-5’-monophosphate dehydrogenase assembly. Journal of Cell Science. 2018;131:jcs223289. doi: 10.1242/jcs.223289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallographica. Section D, Biological Crystallography. 2004;60:2126–2132. doi: 10.1107/S0907444904019158. [DOI] [PubMed] [Google Scholar]
  16. Eriksen TA, Kadziola A, Bentsen AK, Harlow KW, Larsen S. Structural basis for the function of Bacillus subtilis phosphoribosyl-pyrophosphate synthetase. Nature Structural Biology. 2000;7:303–308. doi: 10.1038/74069. [DOI] [PubMed] [Google Scholar]
  17. Fox IH, Kelley WN. Human phosphoribosylpyrophosphate synthetase. Distribution, purification, and properties. The Journal of Biological Chemistry. 1971;246:5739–5748. [PubMed] [Google Scholar]
  18. Gibson KJ, Switzer RL. Structure of the divalent cation.nucleotide complex at the active site of phosphoribosylpyrophosphate synthetase. The Journal of Biological Chemistry. 1980;255:694–696. [PubMed] [Google Scholar]
  19. Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JH, Ferrin TE. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Science. 2018;27:14–25. doi: 10.1002/pro.3235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hove-Jensen B, Harlow KW, King CJ, Switzer RL. Phosphoribosylpyrophosphate synthetase of Escherichia coli. Properties of the purified enzyme and primary structure of the prs gene. The Journal of Biological Chemistry. 1986;261:6765–6771. doi: 10.1016/S0021-9258(19)62682-7. [DOI] [PubMed] [Google Scholar]
  21. Hove-Jensen B. Mutation in the phosphoribosylpyrophosphate synthetase gene (prs) that results in simultaneous requirements for purine and pyrimidine nucleosides, nicotinamide nucleotide, histidine, and tryptophan in Escherichia coli. Journal of Bacteriology. 1988;170:1148–1152. doi: 10.1128/jb.170.3.1148-1152.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hove-Jensen B, Andersen KR, Kilstrup M, Martinussen J, Switzer RL, Willemoës M. Phosphoribosyl Diphosphate (PRPP): Biosynthesis, Enzymology, Utilization, and Metabolic Significance. Microbiology and Molecular Biology Reviews. 2017;81:e00040-16. doi: 10.1128/MMBR.00040-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hunkeler M, Hagmann A, Stuttfeld E, Chami M, Guri Y, Stahlberg H, Maier T. Structural basis for regulation of human acetyl-CoA carboxylase. Nature. 2018;558:470–474. doi: 10.1038/s41586-018-0201-4. [DOI] [PubMed] [Google Scholar]
  24. Jiménez A, Santos MA, Revuelta JL. Phosphoribosyl pyrophosphate synthetase activity affects growth and riboflavin production in Ashbya gossypii. BMC Biotechnology. 2008;8:67. doi: 10.1186/1472-6750-8-67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Johnson MC, Kollman JM. Cryo-EM structures demonstrate human IMPDH2 filament assembly tunes allosteric regulation. eLife. 2020;9:e53243. doi: 10.7554/eLife.53243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kadziola A, Jepsen CH, Johansson E, McGuire J, Larsen S, Hove-Jensen B. Novel class III phosphoribosyl diphosphate synthase: structure and properties of the tetrameric, phosphate-activated, non-allosterically inhibited enzyme from Methanocaldococcus jannaschii. Journal of Molecular Biology. 2005;354:815–828. doi: 10.1016/j.jmb.2005.10.001. [DOI] [PubMed] [Google Scholar]
  27. Khorana HG, Fernandes JF, Kornberg A. Pyrophosphorylation of ribose 5-phosphate in the enzymatic synthesis of 5-phosphorylribose 1-pyrophosphate. The Journal of Biological Chemistry. 1958;230:941–948. [PubMed] [Google Scholar]
  28. Kita K, Otsuki T, Ishizuka T, Tatibana M. Rat liver phosphoribosyl pyrophosphate synthetase: existence of the purified enzyme as heterogeneous aggregates and identification of the catalytic subunit. Journal of Biochemistry. 1989;105:736–741. doi: 10.1093/oxfordjournals.jbchem.a122737. [DOI] [PubMed] [Google Scholar]
  29. Krath BN, Eriksen TA, Poulsen TS, Hove-Jensen B. Cloning and sequencing of cDNAs specifying a novel class of phosphoribosyl diphosphate synthase in Arabidopsis thaliana. Biochimica et Biophysica Acta. 1999;1430:403–408. doi: 10.1016/s0167-4838(99)00022-9. [DOI] [PubMed] [Google Scholar]
  30. Krath BN, Hove-Jensen B. Class II recombinant phosphoribosyl diphosphate synthase from spinach. Phosphate independence and diphosphoryl donor specificity. The Journal of Biological Chemistry. 2001;276:17851–17856. doi: 10.1074/jbc.M010172200. [DOI] [PubMed] [Google Scholar]
  31. Krungkrai SR, DelFraino BJ, Smiley JA, Prapunwattana P, Mitamura T, Horii T, Krungkrai J. A novel enzyme complex of orotate phosphoribosyltransferase and orotidine 5’-monophosphate decarboxylase in human malaria parasite Plasmodium falciparum: physical association, kinetics, and inhibition characterization. Biochemistry. 2005;44:1643–1652. doi: 10.1021/bi048439h. [DOI] [PubMed] [Google Scholar]
  32. Li S, Lu Y, Peng B, Ding J. Crystal structure of human phosphoribosylpyrophosphate synthetase 1 reveals a novel allosteric site. The Biochemical Journal. 2007;401:39–47. doi: 10.1042/BJ20061066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Li B, Li H, Bai Y, Kirschner-Schwabe R, Yang JJ, Chen Y, Lu G, Tzoneva G, Ma X, Wu T, Li W, Lu H, Ding L, Liang H, Huang X, Yang M, Jin L, Kang H, Chen S, Du A, Shen S, Ding J, Chen H, Chen J, von Stackelberg A, Gu L, Zhang J, Ferrando A, Tang J, Wang S, Zhou B-BS. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nature Medicine. 2015;21:563–571. doi: 10.1038/nm.3840. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lin W-C, Chakraborty A, Huang S-C, Wang P-Y, Hsieh Y-J, Chien K-Y, Lee Y-H, Chang C-C, Tang H-Y, Lin Y-T, Tung C-S, Luo J-D, Chen T-W, Lin T-Y, Cheng M-L, Chen Y-T, Yeh C-T, Liu J-L, Sung L-Y, Shiao M-S, Yu J-S, Chang Y-S, Pai L-M. Histidine-Dependent Protein Methylation Is Required for Compartmentalization of CTP Synthase. Cell Reports. 2018;24:2733–2745. doi: 10.1016/j.celrep.2018.08.007. [DOI] [PubMed] [Google Scholar]
  35. Liu JL. Intracellular compartmentation of CTP synthase in Drosophila. Journal of Genetics and Genomics = Yi Chuan Xue Bao. 2010;37:281–296. doi: 10.1016/S1673-8527(09)60046-1. [DOI] [PubMed] [Google Scholar]
  36. Liu JL. The Cytoophidium and Its Kind: Filamentation and Compartmentation of Metabolic Enzymes. Annual Review of Cell and Developmental Biology. 2016;32:349–372. doi: 10.1146/annurev-cellbio-111315-124907. [DOI] [PubMed] [Google Scholar]
  37. Lynch EM, Hicks DR, Shepherd M, Endrizzi JA, Maker A, Hansen JM, Barry RM, Gitai Z, Baldwin EP, Kollman JM. Human CTP synthase filament structure reveals the active enzyme conformation. Nature Structural & Molecular Biology. 2017;24:507–514. doi: 10.1038/nsmb.3407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Lynch EM, Kollman JM. Coupled structural transitions enable highly cooperative regulation of human CTPS2 filaments. Nature Structural & Molecular Biology. 2020;27:42–48. doi: 10.1038/s41594-019-0352-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Mastronarde DN. Automated electron microscope tomography using robust prediction of specimen movements. Journal of Structural Biology. 2005;152:36–51. doi: 10.1016/j.jsb.2005.07.007. [DOI] [PubMed] [Google Scholar]
  40. Meyrat A, von Ballmoos C. ATP synthesis at physiological nucleotide concentrations. Scientific Reports. 2019;9:3070. doi: 10.1038/s41598-019-38564-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Munch-Petersen A. Metabolism of Nucleotides, Nucleosides and Nucleobases in Microorganisms. NIH Library; 1983. [Google Scholar]
  42. Noree C, Sato BK, Broyer RM, Wilhelm JE. Identification of novel filament-forming proteins in Saccharomyces cerevisiae and Drosophila melanogaster. The Journal of Cell Biology. 2010;190:541–551. doi: 10.1083/jcb.201003001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Noree C, Begovich K, Samilo D, Broyer R, Monfort E, Wilhelm JE. A quantitative screen for metabolic enzyme structures reveals patterns of assembly across the yeast metabolic network. Molecular Biology of the Cell. 2019;30:2721–2736. doi: 10.1091/mbc.E19-04-0224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Nosal JM, Switzer RL, Becker MA. Overexpression, purification, and characterization of recombinant human 5-phosphoribosyl-1-pyrophosphate synthetase isozymes I and II. The Journal of Biological Chemistry. 1993;268:10168–10175. doi: 10.1016/S0021-9258(18)82187-1. [DOI] [PubMed] [Google Scholar]
  45. Park CK, Horton NC. Structures, functions, and mechanisms of filament forming enzymes: a renaissance of enzyme filamentation. Biophysical Reviews. 2019;11:927–994. doi: 10.1007/s12551-019-00602-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Peng M, Chang CC, Liu JL, Sung LY. CTPS and IMPDH form cytoophidia in developmental thymocytes. Experimental Cell Research. 2021;405:112662. doi: 10.1016/j.yexcr.2021.112662. [DOI] [PubMed] [Google Scholar]
  47. Petrovska I, Nüske E, Munder MC, Kulasegaran G, Malinovska L, Kroschwald S, Richter D, Fahmy K, Gibson K, Verbavatz JM, Alberti S. Filament formation by metabolic enzymes is a specific adaptation to an advanced state of cellular starvation. eLife. 2014;3:e02409. doi: 10.7554/eLife.02409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera--a visualization system for exploratory research and analysis. Journal of Computational Chemistry. 2004;25:1605–1612. doi: 10.1002/jcc.20084. [DOI] [PubMed] [Google Scholar]
  49. Shen QJ, Kassim H, Huang Y, Li H, Zhang J, Li G, Wang PY, Yan J, Ye F, Liu JL. Filamentation of Metabolic Enzymes in Saccharomyces cerevisiae. Journal of Genetics and Genomics = Yi Chuan Xue Bao. 2016;43:393–404. doi: 10.1016/j.jgg.2016.03.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Sun Z, Liu JL. Forming cytoophidia prolongs the half-life of CTP synthase. Cell Discovery. 2019a;5:32. doi: 10.1038/s41421-019-0098-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Sun Z, Liu JL. mTOR-S6K1 pathway mediates cytoophidium assembly. Journal of Genetics and Genomics = Yi Chuan Xue Bao. 2019b;46:65–74. doi: 10.1016/j.jgg.2018.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Tatibana M, Kita K, Taira M, Ishijima S, Sonoda T, Ishizuka T, Iizasa T, Ahmad I. Mammalian phosphoribosyl-pyrophosphate synthetase. Advances in Enzyme Regulation. 1995;35:229–249. doi: 10.1016/0065-2571(94)00017-w. [DOI] [PubMed] [Google Scholar]
  53. Traut TW. Physiological concentrations of purines and pyrimidines. Molecular and Cellular Biochemistry. 1994;140:1–22. doi: 10.1007/BF00928361. [DOI] [PubMed] [Google Scholar]
  54. Wang PY, Lin WC, Tsai YC, Cheng ML, Lin YH, Tseng SH, Chakraborty A, Pai LM. Regulation of CTP Synthase Filament Formation During DNA Endoreplication in Drosophila. Genetics. 2015;201:1511–1523. doi: 10.1534/genetics.115.180737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Willemoës M, Hove-Jensen B, Larsen S. Steady state kinetic model for the binding of substrates and allosteric effectors to Escherichia coli phosphoribosyl-diphosphate synthase. The Journal of Biological Chemistry. 2000;275:35408–35412. doi: 10.1074/jbc.M006346200. [DOI] [PubMed] [Google Scholar]
  56. Williams CJ, Headd JJ, Moriarty NW, Prisant MG, Videau LL, Deis LN, Verma V, Keedy DA, Hintze BJ, Chen VB, Jain S, Lewis SM, Arendall WB, Snoeyink J, Adams PD, Lovell SC, Richardson JS, Richardson DC. MolProbity: More and better reference data for improved all-atom structure validation. Protein Science. 2018;27:293–315. doi: 10.1002/pro.3330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Zakataeva NP, Romanenkov DV, Skripnikova VS, Vitushkina MV, Livshits VA, Kivero AD, Novikova AE. Wild-type and feedback-resistant phosphoribosyl pyrophosphate synthetases from Bacillus amyloliquefaciens: purification, characterization, and application to increase purine nucleoside production. Applied Microbiology and Biotechnology. 2012;93:2023–2033. doi: 10.1007/s00253-011-3687-3. [DOI] [PubMed] [Google Scholar]
  58. Zhang S, Ding K, Shen QJ, Zhao S, Liu JL. Filamentation of asparagine synthetase in Saccharomyces cerevisiae. PLOS Genetics. 2018;14:e1007737. doi: 10.1371/journal.pgen.1007737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Zhang J, Liu JL. Temperature-sensitive cytoophidium assembly in Schizosaccharomyces pombe. Journal of Genetics and Genomics = Yi Chuan Xue Bao. 2019;46:423–432. doi: 10.1016/j.jgg.2019.09.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Zhang Y, Liu J, Liu JL. The atlas of cytoophidia in Drosophila larvae. Journal of Genetics and Genomics = Yi Chuan Xue Bao. 2020a;47:321–331. doi: 10.1016/j.jgg.2020.06.004. [DOI] [PubMed] [Google Scholar]
  61. Zhang B, Tastan ÖY, Zhou X, Guo CJ, Liu X, Thind A, Hu HH, Zhao S, Liu JL. The proline synthesis enzyme P5CS forms cytoophidia in Drosophila. Journal of Genetics and Genomics = Yi Chuan Xue Bao. 2020b;47:131–143. doi: 10.1016/j.jgg.2020.02.005. [DOI] [PubMed] [Google Scholar]
  62. Zhang S, Feng HC, Liu JL. ASNS disruption shortens CTPS cytoophidia in Saccharomyces cerevisiae. G3 (Bethesda, Md.) 2021;11:jkaa060. doi: 10.1093/g3journal/jkaa060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Zheng SQ, Palovcak E, Armache JP, Verba KA, Cheng Y, Agard DA. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nature Methods. 2017;14:331–332. doi: 10.1038/nmeth.4193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Zhong J, Guo CJ, Zhou X, Chang CC, Yin B, Zhang T, Hu HH, Lu GM, Liu JL. Structural basis of dynamic P5CS filaments. eLife. 2022;11:e76107. doi: 10.7554/eLife.76107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Zhou X, Guo CJ, Hu HH, Zhong J, Sun Q, Liu D, Zhou S, Chang CC, Liu JL. Drosophila CTP synthase can form distinct substrate- and product-bound filaments. Journal of Genetics and Genomics = Yi Chuan Xue Bao. 2019a;46:537–545. doi: 10.1016/j.jgg.2019.11.006. [DOI] [PubMed] [Google Scholar]
  66. Zhou W, Tsai A, Dattmore DA, Stives DP, Chitrakar I, D’alessandro AM, Patil S, Hicks KA, French JB. Crystal structure of E. coli PRPP synthetase. BMC Structural Biology. 2019b;19:1–7. doi: 10.1186/s12900-019-0100-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Zhou S, Xiang H, Liu JL. CTP synthase forms cytoophidia in archaea. Journal of Genetics and Genomics = Yi Chuan Xue Bao. 2020;47:213–223. doi: 10.1016/j.jgg.2020.03.004. [DOI] [PubMed] [Google Scholar]
  68. Zhou X, Guo CJ, Chang CC, Zhong J, Hu HH, Lu GM, Liu JL. Structural basis for ligand binding modes of CTP synthase. PNAS. 2021;118:e2026621118. doi: 10.1073/pnas.2026621118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Zivanov J, Nakane T, Forsberg BO, Kimanius D, Hagen WJ, Lindahl E, Scheres SH. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife. 2018;7:e42166. doi: 10.7554/eLife.42166. [DOI] [PMC free article] [PubMed] [Google Scholar]

Editor's evaluation

Edward H Egelman 1

This paper provides new insights into how polymerization into two different structures modulates the activity of the enzyme PRPS. The molecular mechanisms proposed are supported by the data, and likely to be of general interest.

Decision letter

Editor: Edward H Egelman1

Our editorial process produces two outputs: i) public reviews designed to be posted alongside the preprint for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.

Decision letter after peer review:

Thank you for submitting your article "Allosteric inhibition of PRPS is moderated by filamentous polymerization" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Philip Cole as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.

Essential revisions:

While all three reviewers found the work significant and of potential broad interest, all felt that the paper needed major rewriting to improve the clarity and language. Numerous examples are given below where improvements are needed.

Reviewer #1 (Recommendations for the Authors):

The paper needs careful rewriting, and authors should check and review extensively for improvements to the use of English. Here are just three examples out of many that I found:

(line 57) "…outcomes in clinical."

(line 73) "the ADP" should be "ADP".

(line 352-4) "We fused the sequences of PRPSWT and PRPSR302A, PRPSY24A and PRPSR302A/Y24A mutants were with mCherry and overexpressed them in E. coli individually."

Reviewer #2 (Recommendations for the Authors):

The manuscript reports impressive high-quality cryo-EM reconstructions of two different PRPP synthetase filaments. The detailed structural analysis, combined with structure-based mutagenesis and enzymatic assays reveals a quite complex regulatory mechanism for this important enzyme. I realize the difficulty of the study, given that ADP can bind to three different sites with different effects on the protein activity, and this makes the analysis very difficult. The finding that the assembly of the enzyme in two different filamentous structures and the repositioning of the regulatory loop can affect the binding of ADP to the different regulatory sites, and the binding of the substrates is very interesting.

I encourage the authors to review carefully the manuscript to facilitate the comprehension of the main message.

Reviewer #3 (Recommendations for the Authors):

1. Some language editing would aid in the clarity of the text (throughout the manuscript).

2. Species names should be italicized.

3. Page 5, line 85: "The cytoophidium is assembled by bunding filamentous polymers of metabolic enzymes" – is this known for all cytoophidia? If so, a reference should be given. If not, the sentence can be rewritten to indicate that this is speculation or based on some evidence in some cases.

4. Page 6, line 94: the sentence "The polymerizations of CTPS and IMPDH have been demonstrated to desensitize the proteins to end-product inhibition or allosteric inhibition effects, suggesting its physiological functions in tuning intracellular nucleotide levels". Please provide a reference to support this statement. Also, is this true in all cases of CTPS/IMPDH polymerization?

5. Page 9, line 150: what was the concentration of Mg2+ used in the structure with 2 mM ATP (and no π I presume?)

6. Page 9, lines 157 and 167, please state the handedness of the twist of the polymers.

7. Page 9, line 157, it is stated that R5P is found in the active site, though it was not added to the enzyme before structural studies were conducted. The authors suggest that it may have copurified with the PRPS, but it is not present in the Type B filament structure. The authors also do not show the map around the R5P. The map should be shown to provide confidence in the assignment of R5P to the map in the active site. Could it be formed from the degradation of ATP (just as the ADP and π presumably are?).

8. page 9, line 163 and elsewhere: it's awkward to refer to the structure of L. pneumophila as a model. It should be referred to as an x-ray crystal structure (if indeed that is what it is).

9. Figure 2 and text regarding panels in figure 2. It is difficult to deconvolute all the structures and alignments without referencing the figure legend constantly. It would be easier if structures were identified in the panels, such as by color coding their name/type in the panel where they are shown in particular colors. When colors are ambiguous (such as in panel 2e, a label and arrow would aid in distinguishing the type A from the type B conformation of the RF loop). In the text, when a particular structure is being indicated, the color of that structure in addition to the panel id should be given (e.g. "yellow, Figure 2c").

10. Page 10, line 169: "ATP binding site and the allosteric site 1 are not bound by any ligand". Should this read "allosteric site 2"?

11. Page 10, line 183: some object to the use of the word "monomer" in the context of an oligomer. A protein chain or subunit or protomer would be more appropriate.

12. It is interesting that the allosteric sites and active sites are found between protein chains in the hexamer, yet this isn't mentioned.

13. page 11, line 190. "His131 and the phosphate". please indicate which phosphate (it appears to be the β).

14. page 11, 205-206. regarding the second type A filament structure, which was incubated apparently in both AMP and ADP, how is it determined that both AMP and ADP are bound in site 2? Was refinement done with partial occupancy of each? The sentence describing this structure indicates at first that AMP is in site 2, then the next sentence indicates that ADP is bound. Which is it? this should be more clear.

15. page 11, line 208. should guanine be adenine?

16. page 11, line 211, "and residues responsible for the binding", please indicate which residues. Also, in figure 2, highlight the residues suggested to be conserved. Residues suggested to be involved in binding to ligands include 102, 178, 182, 149, 133, and 147, however, 178, 182, and 149 do not appear to be conserved. Also, are residues of site 1 conserved? if not, what would that mean?

17. page 12, lines 229 and 231, why are the B factors negative?

18. page 12, line 232, should "figure 2f" be figure 2e?

19. Page 12, line 218, it should be indicated that allosteric site 1 is the site being discussed.

20. page 12, line 220. Although ATP binds only in the active site, it should be indicated whenever the ATP binding site is mentioned that it is the ATP binding site in the active site (since it is hard to keep track of which site binds which type of nucleotide).

21. page 12, line 220, which phosphate binding site of R5P does π bind at?

22. page 12, line 233, "In the stable conformation", is this of the type A filament? If so, it should be indicated.

23. Use of apostrophes or asterisks on the residue names in the second paragraph (beginning at line 244) of page 13 would help to show that residues are contributed by different subunits.

24. page 13, line 250, indicate which atom of Leu23 hydrogen bonds to Arg301 (presumably the carbonyl oxygen of the main chain of Leu23?).

25. page 15, line 280: indicate panel c of Sup 5. Also, what are the concentrations of ligands kept at constant concentrations in Sup 5? (e.g. the concentration of ATP when R5P is varied?). What is the concentration of the enzyme?

26. page 16, line 315, "the allosteric inhibition", indicate that it is by ADP, i.e. "allosteric inhibition by ADP".

27. page 16, line 319, "enhance the inhibitory effect" to "enhance the inhibitory effect of ADP".

28. page 17, line 328, "Since AMP is supposedly unable to bind at the allosteric site 1", please provide a reference and/or rationale to support this assertion.

29. page 21, line 400, "Although some filamentous polymers of metabolic enzymes were demonstrated to accommodate different states of the proteins, their protomers in various states assemble through the same interfaces and can either boost or suppress the activity". References for CTPS are given here although the interfaces in CTPS filaments that are activated differ from those which are inhibited. This is true when CTPS from different organisms are compared. Please correct or clarify what is meant by this sentence as it appears to indicate that for CTPS, one type of filament forms which can accommodate either active or inactive conformations. Further, there are other enzymes for which different interfaces result in different filamentous forms, with differing activity, for example, ACC enzyme.

30. page 22, line 432: "According to our models, both allosteric site 1 and site 2 could be responsible for the binding of the second ADP in these conditions". It seems as though the conclusion of the paper is that ADP binding at allosteric site 1 would block ATP binding to the active site. Is this not true?

31. Page 38, line 689, please indicate allosteric site 1 in "while the allosteric site".

32. Colors in Figure 2, panels d and f need to be defined in the figure legend.

33. page 40, line 708: "negative staining" should read "negative staining electron microscopy" (and elsewhere in the manuscript).

34. Please define the meaning of ***, and so on in the figures.

35. Please define "S.E.M." in figure 3e legend.

36. figure 4b, why is "n.s." shown for the orange line (the double mutant with mCherry)? It is true that the growth of this mutant is similar to wild type without mCherry, but it is much less when compared to the growth of wild type with mCherry.

37. π is found in the type A filament, yet it is absent from the type A filament shown in panel 4c. It also competes for binding with ADP in site 1. Should the "+Pi" be located with the other arrow, to type A, and not type B?

38. In Figure 4a, the text of the superscripts is very small.

39. Please provide some explanation of the model shown in figure 4c in the figure legend.

40. Please provide the concentrations of ligands (AMP, ADP, ATP, etc) in each image of Figure S1.

41. Please indicate somehow that the phosphate ion shown in Figure S2c is derived only from the type A filament (and not the type AAMP/ADP).

eLife. 2022 Jun 23;11:e79552. doi: 10.7554/eLife.79552.sa2

Author response

Reviewer #1 (Recommendations for the Authors):

The paper needs careful rewriting, and authors should check and review extensively for improvements to the use of English. Here are just three examples out of many that I found:

(line 57) "…outcomes in clinical."

(line 73) "the ADP" should be "ADP".

(line 352-4) "We fused the sequences of PRPSWT and PRPSR302A, PRPSY24A and PRPSR302A/Y24A mutants were with mCherry and overexpressed them in E. coli individually."

We have rewritten the manuscript to improve the clarity and presentation.

Reviewer #3 (Recommendations for the Authors):

1. Some language editing would aid in the clarity of the text (throughout the manuscript).

We have rewritten the manuscript to improve the clarity and presentation.

2. Species names should be italicized.

Revised.

3. Page 5, line 85: "The cytoophidium is assembled by bunding filamentous polymers of metabolic enzymes" – is this known for all cytoophidia? If so, a reference should be given. If not, the sentence can be rewritten to indicate that this is speculation or based on some evidence in some cases.

By definition, all cytoophidia are bundled filamentous polymers of metabolic enzymes. Related references have been added.

4. Page 6, line 94: the sentence "The polymerizations of CTPS and IMPDH have been demonstrated to desensitize the proteins to end-product inhibition or allosteric inhibition effects, suggesting its physiological functions in tuning intracellular nucleotide levels". Please provide a reference to support this statement. Also, is this true in all cases of CTPS/IMPDH polymerization?

Indeed, some differences may present among species or protein isoforms. We specified human CTPS1 and IMPDH2 in this sentence and added references.

5. Page 9, line 150: what was the concentration of Mg2+ used in the structure with 2 mM ATP (and no π I presume?)

The concentration of Mg2+ has been added in the text. No π in this condition.

6. Page 9, lines 157 and 167, please state the handedness of the twist of the polymers.

Added (left-handed twist) in the description.

7. Page 9, line 157, it is stated that R5P is found in the active site, though it was not added to the enzyme before structural studies were conducted. The authors suggest that it may have copurified with the PRPS, but it is not present in the Type B filament structure. The authors also do not show the map around the R5P. The map should be shown to provide confidence in the assignment of R5P to the map in the active site. Could it be formed from the degradation of ATP (just as the ADP and π presumably are?).

We have added a supplementary figure showing the map around R5P.

8. page 9, line 163 and elsewhere: it's awkward to refer to the structure of L. pneumophila as a model. It should be referred to as an x-ray crystal structure (if indeed that is what it is).

Revised.

9. Figure 2 and text regarding panels in figure 2. It is difficult to deconvolute all the structures and alignments without referencing the figure legend constantly. It would be easier if structures were identified in the panels, such as by color coding their name/type in the panel where they are shown in particular colors. When colors are ambiguous (such as in panel 2e, a label and arrow would aid in distinguishing the type A from the type B conformation of the RF loop). In the text, when a particular structure is being indicated, the color of that structure in addition to the panel id should be given (e.g. "yellow, Figure 2c").

Revised.

10. Page 10, line 169: "ATP binding site and the allosteric site 1 are not bound by any ligand". Should this read "allosteric site 2"?

Corrected.

11. Page 10, line 183: some object to the use of the word "monomer" in the context of an oligomer. A protein chain or subunit or protomer would be more appropriate.

Revised.

12. It is interesting that the allosteric sites and active sites are found between protein chains in the hexamer, yet this isn't mentioned.

We have now mentioned in the text.

13. page 11, line 190. "His131 and the phosphate". please indicate which phosphate (it appears to be the β).

It is the α phosphate. Revised accordingly.

14. page 11, 205-206. regarding the second type A filament structure, which was incubated apparently in both AMP and ADP, how is it determined that both AMP and ADP are bound in site 2? Was refinement done with partial occupancy of each? The sentence describing this structure indicates at first that AMP is in site 2, then the next sentence indicates that ADP is bound. Which is it? this should be more clear.

In type AAMP/ADP filament, only AMP is bound to site 2. We revise the sentence to avoid confusion.

15. page 11, line 208. should guanine be adenine?

Corrected.

16. page 11, line 211, "and residues responsible for the binding", please indicate which residues. Also, in figure 2, highlight the residues suggested to be conserved. Residues suggested to be involved in binding to ligands include 102, 178, 182, 149, 133, and 147, however, 178, 182, and 149 do not appear to be conserved. Also, are residues of site 1 conserved? if not, what would that mean?

We revised the figure accordingly (New Figure 3 and Figure 3 —figure supplement 2).

17. page 12, lines 229 and 231, why are the B factors negative?

It should be positive. Corrected.

18. page 12, line 232, should "figure 2f" be figure 2e?

Corrected.

19. Page 12, line 218, it should be indicated that allosteric site 1 is the site being discussed.

Modified.

20. page 12, line 220. Although ATP binds only in the active site, it should be indicated whenever the ATP binding site is mentioned that it is the ATP binding site in the active site (since it is hard to keep track of which site binds which type of nucleotide).

Modified.

21. page 12, line 220, which phosphate binding site of R5P does π bind at?

Pi binds at the 5-phosphate binding site of R5P.

22. page 12, line 233, "In the stable conformation", is this of the type A filament? If so, it should be indicated.

The sentence is modified.

23. Use of apostrophes or asterisks on the residue names in the second paragraph (beginning at line 244) of page 13 would help to show that residues are contributed by different subunits.

Modified.

24. page 13, line 250, indicate which atom of Leu23 hydrogen bonds to Arg301 (presumably the carbonyl oxygen of the main chain of Leu23?).

Added.

25. page 15, line 280: indicate panel c of Sup 5. Also, what are the concentrations of ligands kept at constant concentrations in Sup 5? (e.g. the concentration of ATP when R5P is varied?). What is the concentration of the enzyme?

We added detail description of the reaction mixtures in the text and legends.

26. page 16, line 315, "the allosteric inhibition", indicate that it is by ADP, i.e. "allosteric inhibition by ADP".

The paragraph has been modified.

27. page 16, line 319, "enhance the inhibitory effect" to "enhance the inhibitory effect of ADP".

The paragraph has been modified.

28. page 17, line 328, "Since AMP is supposedly unable to bind at the allosteric site 1", please provide a reference and/or rationale to support this assertion.

This sentence is removed to avoid confusion.

29. page 21, line 400, "Although some filamentous polymers of metabolic enzymes were demonstrated to accommodate different states of the proteins, their protomers in various states assemble through the same interfaces and can either boost or suppress the activity". References for CTPS are given here although the interfaces in CTPS filaments that are activated differ from those which are inhibited. This is true when CTPS from different organisms are compared. Please correct or clarify what is meant by this sentence as it appears to indicate that for CTPS, one type of filament forms which can accommodate either active or inactive conformations. Further, there are other enzymes for which different interfaces result in different filamentous forms, with differing activity, for example, ACC enzyme.

We revised the sentences to

“Filamentous polymers of some metabolic enzymes have been demonstrated to accommodate different states of proteins. In most cases, their protomers in various states are assembled through the same interface, which can enhance (e.g. human IMPDH, CTPS and Drosophila CTPS) or inhibit (e.g. E. coli CTPS) activity (Johnson and Kollman, 2020; Lynch and Kollman, 2020; Zhou et al., 2021; Zhou et al., 2019b). In other cases, enzymes can polymerize into multiple polymer types (e.g. human acetyl-CoA carboxylase) through different interfaces (Hunkeler et al., 2018)”.

30. page 22, line 432: "According to our models, both allosteric site 1 and site 2 could be responsible for the binding of the second ADP in these conditions". It seems as though the conclusion of the paper is that ADP binding at allosteric site 1 would block ATP binding to the active site. Is this not true?

We removed the confusing sentence.

31. Page 38, line 689, please indicate allosteric site 1 in "while the allosteric site".

Added.

32. Colors in Figure 2, panels d and f need to be defined in the figure legend.

Corrected.

33. page 40, line 708: "negative staining" should read "negative staining electron microscopy" (and elsewhere in the manuscript).

Corrected.

34. Please define the meaning of ***, and so on in the figures.

Added *p < 0.05, ** p < 0.01 and *** p < 0.001. in figure legends.

35. Please define "S.E.M." in figure 3e legend.

Edited to Error bars = standard error of the mean (S.E.M.).

36. figure 4b, why is "n.s." shown for the orange line (the double mutant with mCherry)? It is true that the growth of this mutant is similar to wild type without mCherry, but it is much less when compared to the growth of wild type with mCherry.

Here “wild type with mCherry” means “overexpression of wild-type PRPS fused with mCherry”. We revised figure legends accordingly.

37. π is found in the type A filament, yet it is absent from the type A filament shown in panel 4c. It also competes for binding with ADP in site 1. Should the "+Pi" be located with the other arrow, to type A, and not type B?

We added “+Pi” to the arrow to type A.

38. In Figure 4a, the text of the superscripts is very small.

Modified.

39. Please provide some explanation of the model shown in figure 4c in the figure legend.

Added.

40. Please provide the concentrations of ligands (AMP, ADP, ATP, etc) in each image of Figure S1.

Added.

41. Please indicate somehow that the phosphate ion shown in Figure S2c is derived only from the type A filament (and not the type AAMP/ADP).

We added the following sentence to explain why there is no π in the type AAMP/ADP model:

“In addition, the allosteric site 1 in type AAMP/ADP model is empty, supporting that the presence of ADP and π in the former type A filament model were due to spontaneous hydrolysis of ATP”.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Citations

    1. Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A filament bound with ADP, Pi and R5P. RCSB Protein Data Bank. 7XMU
    2. Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type B filament bound with Pi. RCSB Protein Data Bank. 7XN3
    3. Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A(AMP/ADP) filament bound with ADP, AMP and R5P. RCSB Protein Data Bank. 7XMV
    4. Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A filament bound with ADP, Pi and R5P. Electron Microscopy Data Bank. EMD-33305
    5. Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A (AMP/ADP) filament bound with ADP, AMP and R5P. Electron Microscopy Data Bank. EMD-33306
    6. Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type B filament bound with Pi. Electron Microscopy Data Bank. EMD-33309

    Supplementary Materials

    MDAR checklist
    elife-79552-mdarchecklist1.docx (100.2KB, docx)

    Data Availability Statement

    Atomic models generated in this study have been deposited at the PDB under the accession codes 7XMU, 7XMV, 7XN3. Cryo-EM maps deposited to EMDB as: EMD-33305, EMD-33306, EMD-33309.

    The following datasets were generated:

    Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A filament bound with ADP, Pi and R5P. RCSB Protein Data Bank. 7XMU

    Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type B filament bound with Pi. RCSB Protein Data Bank. 7XN3

    Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A(AMP/ADP) filament bound with ADP, AMP and R5P. RCSB Protein Data Bank. 7XMV

    Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A filament bound with ADP, Pi and R5P. Electron Microscopy Data Bank. EMD-33305

    Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A (AMP/ADP) filament bound with ADP, AMP and R5P. Electron Microscopy Data Bank. EMD-33306

    Hu HH, Lu GM, Chang CC, Liu JL. 2022. E.coli phosphoribosylpyrophosphate (PRPP) synthetase type B filament bound with Pi. Electron Microscopy Data Bank. EMD-33309

    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES